Core Viewpoint - The announcement highlights the completion of the first patient enrollment in the global multi-center Phase II clinical trial of CS2009, a novel tri-specific antibody targeting PD-1, VEGFA, and CTLA-4, by the company [1] Group 1: Clinical Trial Progress - The Phase II clinical trial for CS2009 has commenced in Australia and China, with plans to expand to the United States in the future [1] - The first patient has been enrolled in Australia, indicating progress in the trial [1] Group 2: Product Overview - CS2009 is a tri-specific antibody developed independently by the company, designed to target PD-1, VEGFA, and CTLA-4, showcasing potential as a first-in-class or best-in-class therapy [1] - The antibody aims to achieve multi-dimensional anti-tumor effects through its synergistic action [1] - CS2009 features a differentiated molecular design that combines three clinically validated targets, capable of reactivating exhausted tumor-infiltrating T cells [1] - The product demonstrates neutralizing capability against VEGF comparable to existing anti-VEGF antibodies [1] Group 3: Disease Coverage - The therapeutic scope of CS2009 is extensive, covering various cancers including but not limited to non-small cell lung cancer, small cell lung cancer, liver cancer, gastric cancer, ovarian cancer, cervical cancer, breast cancer, colorectal cancer, and esophageal cancer [1]
基石药业-B(02616.HK)：CS2009(PD-1/VEGF/CTLA-4三特异性抗体)II期临床试验于澳大利亚完成首例患者入组